Redmile Group, LLC Scholar Rock Holding Corp Transaction History

Redmile Group, LLC

$952 Million
Q1 2025

A detailed history of Redmile Group, LLC transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Redmile Group, LLC holds 4,398,281 shares of SRRK stock, worth $176 Million. This represents 14.86% of its overall portfolio holdings.

Number of Shares

4,398,281

Previous 4,549,881 3.33%

Holding current value

$176 Million

Previous $197 Million 28.09%

% of portfolio

14.86%

Previous 15.38%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$32.15 - $45.55 $4.87 Million - $6.91 Million	-151,600 Reduced 3.33%	4,398,281 $141 Million
Q4 2024 Feb 14, 2025	SELL	$7.07 - $45.73 $4.87 Million - $31.5 Million	-688,956 Reduced 13.15%	4,549,881 $197 Million
Q3 2024 Nov 14, 2024	SELL	$7.63 - $9.71 $1.63 Million - $2.08 Million	-214,246 Reduced 3.93%	5,238,837 $42 Million
Q2 2024 Aug 14, 2024	SELL	$7.84 - $16.79 $7.58 Million - $16.2 Million	-966,527 Reduced 15.06%	5,453,083 $45.4 Million
Q1 2024 May 15, 2024	BUY	$13.2 - $17.76 $225,786 - $303,784	17,105 Added 0.27%	6,419,610 $114 Million
Q4 2023 Feb 14, 2024	BUY	$6.52 - $20.32 $13 Million - $40.6 Million	1,998,665 Added 45.38%	6,402,505 $120 Million
Q2 2023 Aug 14, 2023	BUY	$5.79 - $9.11 $7.41 Million - $11.7 Million	1,279,614 Added 40.96%	4,403,840 $33.2 Million
Q1 2023 May 15, 2023	BUY	$7.36 - $12.72 $7.57 Million - $13.1 Million	1,028,406 Added 49.07%	3,124,226 $25 Million
Q4 2022 Feb 14, 2023	SELL	$7.02 - $9.76 $7.33 Million - $10.2 Million	-1,044,206 Reduced 33.25%	2,095,820 $19 Million
Q3 2022 Nov 14, 2022	SELL	$5.33 - $11.3 $1.41 Million - $2.98 Million	-263,900 Reduced 7.75%	3,140,026 $21.8 Million
Q2 2022 Aug 15, 2022	BUY	$4.66 - $13.96 $4.64 Million - $13.9 Million	996,600 Added 41.4%	3,403,926 $18.7 Million
Q1 2022 May 16, 2022	SELL	$11.89 - $24.68 $482,734 - $1 Million	-40,600 Reduced 1.66%	2,407,326 $31 Million
Q4 2021 Feb 14, 2022	SELL	$24.14 - $35.18 $2.47 Million - $3.6 Million	-102,279 Reduced 4.01%	2,447,926 $60.8 Million
Q3 2021 Nov 15, 2021	BUY	$27.38 - $42.21 $6.66 Million - $10.3 Million	243,177 Added 10.54%	2,550,205 $84.2 Million
Q2 2021 Aug 16, 2021	BUY	$26.34 - $46.62 $3.43 Million - $6.08 Million	130,400 Added 5.99%	2,307,028 $66.7 Million
Q1 2021 May 17, 2021	SELL	$45.96 - $68.02 $33.1 Million - $49 Million	-719,961 Reduced 24.86%	2,176,628 $110 Million
Q4 2020 Feb 16, 2021	SELL	$13.72 - $51.57 $58,996 - $221,751	-4,300 Reduced 0.15%	2,896,589 $141 Million
Q3 2020 Nov 16, 2020	BUY	$10.54 - $18.47 $263,500 - $461,750	25,000 Added 0.87%	2,900,889 $51.3 Million
Q2 2020 Aug 14, 2020	SELL	$10.37 - $20.64 $147,254 - $293,088	-14,200 Reduced 0.49%	2,875,889 $52.4 Million
Q1 2020 May 15, 2020	SELL	$9.63 - $17.14 $489,204 - $870,712	-50,800 Reduced 1.73%	2,890,089 $35 Million
Q4 2019 Feb 14, 2020	BUY	$7.2 - $13.2 $601,200 - $1.1 Million	83,500 Added 2.92%	2,940,889 $38.8 Million
Q3 2019 Nov 14, 2019	SELL	$8.95 - $15.72 $563,850 - $990,360	-63,000 Reduced 2.16%	2,857,389 $25.6 Million
Q2 2019 Aug 14, 2019	BUY	$14.61 - $22.45 $12.7 Million - $19.5 Million	869,300 Added 42.38%	2,920,389 $46.3 Million
Q1 2019 May 15, 2019	BUY	$14.24 - $22.28 $4.13 Million - $6.45 Million	289,682 Added 16.45%	2,051,089 $38.5 Million
Q4 2018 Feb 14, 2019	SELL	$17.86 - $28.77 $208,962 - $336,609	-11,700 Reduced 0.66%	1,761,407 $40.5 Million
Q3 2018 Nov 14, 2018	BUY	$13.39 - $26.25 $303,939 - $595,848	22,699 Added 1.3%	1,773,107 $45.7 Million
Q2 2018 Aug 14, 2018	BUY	$15.0 - $25.6 $26.3 Million - $44.8 Million	1,750,408 New	1,750,408 $27.3 Million

Others Institutions Holding SRRK

# of Institutions

251

Shares Held

89.8M

Call Options Held

706K

Put Options Held

456K

View Full List

About Scholar Rock Holding Corp

Ticker SRRK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,640,600
Market Cap $2.06B
Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...

More about SRRK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Account

Redmile Group, LLC Scholar Rock Holding Corp Transaction History